FRCA Notes


Abdominal Aortic Aneurysms: Background and Pathophysiology


  • An abdominal aortic aneurysm (AAA) is a permanent dilatation of the abdominal aorta to >3cm, or >1.5 times its normal diameter
  • The normal aortic diameter is ~2cm, and is smaller in women and some ethnic groups, so a fixed 3cm threshold may under-diagnose AAA in these groups

  • AAAs are classified by their relationship to the renal arteries
    • Infra-renal (the large majority)
    • Juxta-renal
    • Para-renal
    • Supra-renal

  • Anything above an infra-renal aneurysm is termed a 'complex' AAA, which has implications for both the level of cross-clamping in open repair and the type of graft needed for EVAR

Epidemiology

  • The incidence of AAA has fallen markedly over recent decades, largely as a result of reduced smoking
  • In the UK screening programme, prevalence in 65-year-old men is now <1%, having been 1.3% in 2013

  • AAA is up to four times less common in women, though women who do develop an AAA have:
    • A higher risk of rupture for any given diameter
    • Higher mortality following both elective and emergency repair

  • Ruptured AAA still accounts for around 6,000 deaths per year in England and Wales

Risk factors


Risk factors for AAA development Risk factors for AAA rupture
Smoking (the strongest risk factor; OR >3) Increasing diameter
Male sex Rapid rate of expansion
Increasing age (>65yrs) Female sex
Family history (heritability up to 70% in twin studies) Current smoking
Hypertension and hyperlipidaemia Hypertension
Coronary, cerebrovascular or peripheral vascular disease
White ethnicity
Connective tissue disease e.g. Marfan's, vascular Ehlers-Danlos

  • Smoking is the most important modifiable risk factor for AAA formation, growth and rupture
  • Diabetes is curiously protective; the risk of developing an AAA is roughly halved, and aneurysms grow more slowly

Pathophysiology

  • AAA is a degenerative disease of the aortic wall, primarily affecting the tunica media
  • Within the aneurysmal segment there are fewer elastin and collagen fibres, and those which remain have poor quality cross-links

  • Wall strength is further compromised by:
    • Chronic inflammatory cell infiltration of the wall
    • Increased protease activity, notably matrix metalloproteinases and elastase, leading to elastin and collagen breakdown
    • Loss of vascular smooth muscle cells
    • Intraluminal mural thrombus, which is metabolically active and promotes local hypoxia, plasminogen activation and further proteolysis

  • As the aneurysm enlarges, wall tension rises (Laplace's law; T = P × r), which promotes further dilatation; a self-perpetuating cycle

Natural history

  • Most small AAAs grow progressively although growth is faster with a larger diameter and continued smoking, and slower in those with diabetes
  • The strongest predictors of rupture are maximum diameter and rate of expansion

  • Rupture risk in small AAAs is low; it is estimated as <1% within 1 year for a 5cm AAA, within 4 years for a 4cm AAA and within 8 years for a 3cm AAA
  • Women have a higher rupture rate than men with aneurysms of the same size
  • The risk rises steeply once the aneurysm exceeds the repair threshold:
Diameter (untreated large AAA) Annual rupture rate
5.5 - 6.0cm 3.5%
6.1 - 7.0cm 4.1%
>7.0cm 6.3%


Diagnosis

  • Intact AAAs are usually clinically silent and found incidentally or on screening
  • Symptoms, if present, include abdominal or back pain, tenderness over the aneurysm, or features of compression of adjacent structures

  • Ultrasound is the first-line tool for diagnosis and surveillance; it is cheap, non-invasive and has a sensitivity and specificity approaching 100%
  • CT angiography is used for treatment planning once the repair threshold is reached, and for the diagnosis of rupture

Screening

  • The NHS AAA Screening Programme (introduced 2009) offers a single abdominal ultrasound to men in the year they turn 65; older men may self-refer
  • Women are not routinely screened, as the low prevalence makes it neither cost-effective nor suitably mortality-reducing
    • NICE suggest considering an aortic ultrasound in women ≥70yrs with risk factors (e.g. COPD, smoking, vascular disease, hypertension, hyperlipidaemia or family history)

  • The Multicentre Aneurysm Screening Study (MASS, 2002) demonstrated a 53% reduction in AAA-related mortality in men aged 65 - 74yrs who:
    1. Attended for screening ultrasound and
    2. Underwent elective repair when the aneurysm diameter reached 5.5cm
  • Population screening reduces aneurysm-related mortality by around 50% and is cost-effective

Surveillance

  • Small aneurysms detected by the NHS programme are followed up with ultrasound at intervals determined by size:
Aortic diameter NHS screening programme action
<3.0cm Normal; discharged
3.0 - 4.4cm (small) Annual ultrasound
4.5 - 5.4cm (medium) 3-monthly ultrasound
≥5.5cm (large) Urgent referral to a vascular surgeon


  • All patients with an AAA should receive cardiovascular risk reduction, as they are far more likely to die from a cardiovascular event than from their aneurysm
    • Smoking cessation, which slows aneurysm growth and reduces rupture risk
    • Blood pressure control
    • Statin therapy
    • Antiplatelet therapy e.g. low-dose aspirin
    • Lifestyle advice including exercise and a healthy diet

  • No drug has been shown to slow aneurysm growth; trials of doxycycline, ACE-inhibitors, β-blockers, ARBs and others have all been negative
  • Exercise (and sexual activity) need not be restricted in patients with a small AAA
  • An AAA is not a contraindication to fluoroquinolone antibiotics, despite earlier regulatory warnings

When to repair

  • Repair is considered when the risk of rupture outweighs the risk of surgery; the generally accepted thresholds are:
    • Men with an asymptomatic AAA ≥5.5cm
    • Women with an asymptomatic AAA ≥5.0cm (reflecting their higher rupture risk)
    • A symptomatic AAA of any size
    • Rapid growth e.g. >1cm in 1 year in an AAA >4cm

  • There is no long-term survival benefit to early repair of AAAs of 4.0 - 5.5cm, according to the UKSAT (1998) and ADAM (2000) trials
  • Patients reaching the threshold should be fast-tracked to vascular review and NICE aim for repair within 8 weeks of referral
  • Elective repair is not recommended for patients with limited life expectancy, by either open or endovascular means

Open repair or EVAR?

  • The decision is made in the vascular MDT (vascular surgeon, interventional radiologist and vascular anaesthetist) with the patient, weighing:
    • Aneurysm anatomy; suitability of the aortic neck and access vessels on CT angiography
    • Physiological fitness and functional capacity
    • Life expectancy
    • Patient preference, including willingness to undergo lifelong surveillance after EVAR

  • Guidelines differ in emphasis, reflecting the trade-off of lower early mortality with EVAR against greater long-term re-intervention and late rupture
  • In practice, younger, fitter patients tend to undergo open repair, and older patients with more comorbidity EVAR
  • Outcomes are better in high-volume centres

Next: Aortic cross-clamp physiology